Latest News & Blog

Inspiring & original thinking. And, the latest news about us.

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

The importance of earlier stage kidney care and why PCPs are the key. A quick Q&A with UCLA’s Dr. Keith Norris. 12.07.22

Why we need to remove race from kidney function equations. A quick Q&A with UCLA’s Dr. Keith Norris. 11.17.22

Should race ever play a role in health care? Find out what UCLA’s Dr. Keith Norris has to say. 11.01.22

Getting FDA approval, a base hit. Getting reimbursement, that’s the ball game. 06.28.22

Is there real value in value-based care? 02.08.22

A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s Dr. Arshad Rahim 01.06.22

An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s, Dr. Amit Sharma 10.26.21

A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer 09.20.21

Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why 08.10.21

3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model 7.27.21

6 Tipping Point Innovations in Kidney Care: A Leading Expert Shares His POV 6.28.21

Why a Shift in Thinking from Kidney Disease to Kidney Health is Mission-Critical. A Candid Conversation with NKF’S Former President & Board Member, Holly Kramer. 6.02.21

NEWS

RenalytixAI Announces Closing of Global Offering and Resulting Total Voting Rights 07.21.20
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower

Read More
RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market 07.16.20
NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs,

Read More
RenalytixAI Announces Launch of Global Offering and Application to List on the Nasdaq Global Market 07.13.20
NEW YORK, July 13, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the commencement of an

Read More
RenalytixAI Announces Partnership with America’s Choice Provider Network for Coverage Expansion 07.08.20
Expands access and coverage of KidneyIntelX™ into key regions for commercial growth NEW YORK, July 8, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved

Read More
RenalytixAI Announces KidneyIntelX Validation Study Accepted for Publication in American Society of Nephrology Journal Kidney360 07.01.20
NEW YORK, July 1, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced that results of a

Read More
RenalytixAI Announces Partnership with the University of Michigan to Extend KidneyIntelX™ Use to Broad CKD Populations and Data Sharing Agreement with a Top Ten Global Pharmaceutical Company 06.30.20
NEW YORK, June 30, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced a partnership with

Read More
RenalytixAI Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual-listing and Global Offering 06.25.20
NEW YORK, June 25, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the public filing of a

Read More
KidneyIntelX™ Receives New York State Approval to Commence Commercial Testing 06.12.20
NEW YORK, June 12, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announced that it has received a

Read More
Renalytix AI Announces Proposed Dual-listing on Nasdaq 05.18.20
NEW YORK, May 18, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has

Read More
RenalytixAI Utah Commercial Laboratory Facility Achieves ISO 13485 Certification 04.27.20
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory

Read More

...